Change in leadership at UMC – WHO Collaborating Centre Uppsala, Sweden

WHO programme / 30 March 2022

Prof. Hervé Le Louët has resigned from his position as CEO of UMC due to family reasons. The recruitment process for next CEO starts immediately. During this interim period, Deputy CEO and former CFO, Birgitta Lindner, will serve as acting CEO, with full support from the Board.

During Le Louët’s tenure as CEO, UMC delivered impressive results. He helped drive forward necessary structural and strategic changes that will continue to be implemented. The Board thanks him for his work and wishes him all the best in the next phase of his career.

UMC’s dedicated and skilled staff will continue business as usual, pursuing their duties in line with the strategy and assignments set by the Board.

You may also like


WHO and UMC enhance data sharing clarity with new VigiBase access conditions

WHO and UMC introduce new VigiBase access conditions, enhancing data sharing clarity and stakeholder confidence in global pharmacovigilance.

20 March 2025

Building better data bridges between pharmacovigilance databases in the Americas and VigiBase

Since 2021 PAHO has assisted 12 countries in importing more than 270,000 historic and new cases to the global database.

27 March 2025

VigiFlow now free for all WHO programme members

Since its introduction 20 years ago, UMC’s adverse event reporting system has become the world’s most widely used safety surveillance toolkit for medicines and vaccines.

25 November 2024